Member Info for wetdream

So, a Phase III of SNG001 started in Feb and is due to complete in Sept?

Seems like late-reported/delayed trades are now a thing of the past.
Weird, innit?

Thanks.

I get the ‘placebo effect’ - and placebo can be a fierce competitor(as Lupuzor /IMM) advocates found to their cost some time ago. Also homeopathy is presumably based on the same principle - the smaller the dose, the more effective the outcome...

In mild cases fair enough, but for a patient with the more severe breathlessness symptoms, I’d imagine that a placebo would be the last thing they’d want or need.

Also, the more effective the drug, the less hospitalisation required if intervention done at the clinically appropriate stage.

Re costs in general, drug costs are upfront and payable now, whereas reduced hospitalisation is recovered ‘down the line’ - possibly after a new government’s in power.

...how SNG001 can ‘fail’ in the ongoing trials?
If a reduction in ‘significant breathlessness’ is a key factor in determining the efficacy of the drug vs placebo, it’d surely be astonishing if administering ‘nothing’ (ie placebo) can cause an improvement in a patient’s outcome.

US government buys it for the US; UK government for the UK; etc etc
They can then charge what their citizens can afford - since each healthcare system is different.
So the governments bear the commercial risk.
Synairgen doesn’t want the Covid price (£) to influence its COPD/Asthma price(£££).

Governments should buy the patent/s.

‘what the point, most of india live below the poverty line, earning less than $1 a day. they are not going to spend $3k on a treatment for their population.’

So India is beyond help then?

Synairgen need to be careful that they’re not backed into a corner where they’re up against the ‘cheap as chips’ steroids like dexamethasone.

Letter sounds like the sporting equivalent of telling Harry Kane at half time he shouldn’t have missed an easy goal chance.
While Marsden may reply out of courtesy, as a holder of 750,000 shares, we must assume he’s not deliberately trying to destroy the company that he and the team have done so much to get so far in such a (relatively) short time.

Currently small numbers perhaps, but if indeed SNG001 is ‘pan-viral’ as believed, then whether it’s Cov1,Cov2, Cov3 etc there should be a future market potential and it may make sense to have stocks of the drug ‘on the shelf’ just to be sure.
Plus, of course, somewhere down the line are the COPD/Asthma patients....

Plenty of six-figure trades going through.
Perhaps someone was impressed - admittedly at 134p....
;-)

Fruitsnveg,
If the severity of a condition can be accurately/dispassionately monitored, then that must surely be preferable to asking the patient a ‘couple of questions’ onnhiw breathless they feel!
Allen & Hanburys developed the PFM in the 70s (interestingly with Holgate’s help) and it revolutionised the identification and treatment of asthma - particularly amongst children - who (not surprisingly) struggled to describe their symptoms.

The challenge is to correctly identify those needy patients in a quantifiable/ measurable way.
It took blood pressure monitoring devices before accurate treatment could be pursued and the introduction of the Peak Flow Meter for asthmatics to accurately measure lung function.
Perhaps the latter device could be adapted to measure degrees of ‘breathlessness’ to facilitate not only hospital treatment pre-ICU, but also aid GPs to intercept patients even earlier?

Last 10 mins trading was like a string of computer code. All single digit algorithms!

Imho Recovery Trial primary purpose was for re-purposing existing drugs. ‘Cheap and cheerful’ was Horby’s famous quote when dexamethasone proved its worth.

Agreed, not appropriate for SNG001.

Pressure building on GSK to ‘do something dramatic’....

https://www.thetimes.co.uk/article/elliott-managements-stake-in-gsk-doomsday-beckons-for-walmsley-3h9zkspgn?shareToken=f6f0eaabb01d2ae5db630ee53f7fbd46

Hi Peelweight,

Agree all your points. In its early days NICE was quite opaque in its determination of what a ‘fair’ NHS price for a new medicine should be and there was a lot of toing and froing. I recall a new treatment for MS was one example where the final price was agreed via such negotiations (guesswork!).
The ‘value for money’ idea (NICE) hasn’t reached mainland Europe yet, I believe, so those countries may have to be dealt with separately.

Peelweight,
You make some good points. And to think I used to think the old PPRS was complicated!
Clearly today’s mantra of ‘affordability’ is driving the current Scheme. No, it’s not the US, but the UK has frequently been a reference country for pricing by other European countries, so may still be important.
I agree that there may well be a way to circumvent this bureaucracy by supplying under a centralised contract (like vaccines) but other than providing some basic input, I think this would be all better left to a JV partner with the experience and infrastructure to take the product further once approved.
The great paradox is that the country with the greatest buying power, the US, also has the highest prices! The trade-off is that they invariably get the latest / newest drugs first.
Money talks.
;-)

Since this topic applies to SNG001 should it gain marketing authorisation, those who have an interest (or who have trouble sleeping) may care to read the current regulations revised a couple of years ago.

Page 45 relates to new branded medicines

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf

It should become pretty clear, on reading this, that Synairgen would be completely unable to comply (not least because they are not a member of the scheme) but also as they have no infrastructure to undertake the scheme’s requirements.

A JV or takeover is essential.

And that’s just the UK....every other country has its own national healthcare system.
There are no shortcuts, imho.

Re the potential pricing of SNG001, perhaps it should be considered in the context of the Track and Trace programme which has cost approx £20bn up to now, with a budget of £37bn over the full two years.

Or, perhaps the £100bn forecast for HS2....